Edwards Lifesciences (NYSE: EW) today announced the results from the RHEIA Trial, a first-of-its-kind trial focused exclusively on outcomes for women receiving transcatheter aortic valve implantation ...

At the European Society of Cardiology Congress 2024, Edwards Lifesciences EW announced the results from the RHEIA Trial — the first-ever study focused exclusively on women receiving transcatheter ...

LONDON, England—Having a small or large annuli does not appear to make a difference for low-risk patients with symptomatic severe aortic stenosis, who have similar 5-year clinical and quality-of-life ...

Female patients with symptomatic, severe aortic stenosis who undergo TAVI with a balloon-expandable Sapien 3 or Sapien 3 Ultra valve (Edwards Lifesciences) see better 1-year outcomes than those ...

Many believe that transcatheter aortic valve implantation is one of the most exciting and lucrative new technologies to hit the market providing an option for patients to sick to undergo open heart ...

Indian-made Myval and Myval Octacor were put to the test against Sapien 3 in the noninferiority trial COMPARE TAVI-1. Noninferiority was demonstrated when counting deaths, strokes, moderate or severe ...

SAPIEN 3, which showed superiority at 1 year, also demonstrates compelling outcomes equivalent to surgery at seven years SAN FRANCISCO--(BUSINESS WIRE)-- Edwards Lifesciences (EW) today announced ...

December 14, 2011 (Quebec City, Quebec City) — A small study has shed more light on atrial fibrillation (AF) following transcatheter aortic valve implantation (TAVI) demonstrating, perhaps most ...

Paris, France, 14-17 May 2024. The Course Directors have selected 3 major Late Breaking Trials (LBTs) that will be presented for the first time during the 2024 edition of EuroPCR. These trials were ...

Irvine-based Edwards Lifesciences Corp. recently shared data on yet another potential market for its Edwards Sapien less-invasive replacement heart valve. Data analysis from the company’s Partner ...